Skip to content

Clinical Characteristics and Molecular Mechanism of Patients With Obstructive Sleep Apnea

Clinical Characteristics and Molecular Mechanism of Patients With Obstructive Sleep Apnea

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07277608
Enrollment
500
Registered
2025-12-11
Start date
2023-08-07
Completion date
2033-08-07
Last updated
2025-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Brief summary

To clarify the clinical features of patients with obstructive sleep apnea; To construct a multi-omics database of patients with obstructive sleep apnea, and compare the effects of different degrees of sleep apnea on prognosis, immunity, and metabolism. The medium and long-term prognosis, complications, comorbidities, risk factors, and immune and metabolic dynamics of patients with sleep apnea after treatment were studied. To elucidate the biomarkers and therapeutic targets associated with obstructive sleep apnea.

Interventions

None listed

Sponsors

Capital Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Patients with suspected obstructive sleep apnea (OSA) admitted to the sleep center of the respiratory Department of Beijing Chaoyang Hospital, Capital Medical University. * Volunteer to participate in the study and sign an informed consent, and can complete at least 1 year of follow-up.

Exclusion criteria

* Patients with obstructive sleep apnea who have been treated with impermanent positive pressure ventilation; * Pregnant or lactating women; * Patients with severe respiratory failure requiring mechanical ventilation; * Patients with severe heart, lung, liver, kidney, and central nervous system damage; * Refuse to participate in follow-up visits and/or take biological samples.

Design outcomes

Primary

MeasureTime frameDescription
Multiple-omics featuresWithin 24 hours of admission,and samples of patients receiving treatment were also collected six months and one year after treatmentELISA ,proteomics and metabolomics were performed on blood, saliva, urine

Countries

China

Contacts

Primary ContactZhiling Zhao
cysleep@163.com+86 186 1280 8859

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026